PIPELINE OVERVIEW
There is significant unmet need for effective therapies for those people whose lives are disrupted by highly debilitating and often fatal neurodegenerative diseases.
Using the NurOwn® technology platform, BrainStorm is focused on realizing the potential of life-changing autologous cellular therapies for the treatment of debilitating neurodegenerative diseases.
NurOwn® MSC-NTF Cells Platform
| Indication | Preclinical | IND Enabling | Phase 1 | Phase 2 | Phase 3a | Phase 3b |
|---|---|---|---|---|---|---|
| Amyotrophic Lateral Sclerosis |
Preclinical
|
IND Enabling
|
Phase 1
|
Phase 2
|
Phase 3a
|
Phase 3b
|
| Progressive Multiple Sclerosis |
Preclinical
|
IND Enabling
|
Phase 1
|
Phase 2
|
Phase 3a
|
Phase 3b
|
| Alzheimer’s Disease |
Preclinical
|
IND Enabling
|
Phase 1
|
Phase 2
|
Phase 3a
|
Phase 3b
|
| Parkinson’s Disease |
Preclinical
|
IND Enabling
|
Phase 1
|
Phase 2
|
Phase 3a
|
Phase 3b
|
| Huntington’s Disease |
Preclinical
|
IND Enabling
|
Phase 1
|
Phase 2
|
Phase 3a
|
Phase 3b
|
| Autism Spectrum Disorder |
Preclinical
|
IND Enabling
|
Phase 1
|
Phase 2
|
Phase 3a
|
Phase 3b
|
| Peripheral Nerve Injury |
Preclinical
|
IND Enabling
|
Phase 1
|
Phase 2
|
Phase 3a
|
Phase 3b
|
NurOwn® MSC-NTF Cells Exosomes off the shelf platform
| Indication | Preclinical | IND Enabling | Phase 1 | Phase 2 | Phase 3a | Phase 3b |
|---|---|---|---|---|---|---|
| ARDS |
Preclinical
|
IND Enabling
|
Phase 1
|
Phase 2
|
Phase 3a
|
Phase 3b
|